Navigation Links
Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
Date:3/11/2011

CAMBRIDGE, Mass. and LONDON, March 11, 2011 /PRNewswire/ -- Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.  

Following preliminary review of the data, no new or unexpected treatment-related safety concerns have emerged during the DEFEND-1 study. Study investigators and regulatory agencies have been notified of the DEFEND-1 study outcome.

GSK will continue to explore additional dosing regimens to inform decisions about the future clinical development programme for otelixizumab.  New recruitment and dosing in the DEFEND-2 study, the ongoing confirmatory Phase 3 study with a design similar to DEFEND-1, has been suspended pending review of the DEFEND-1 results.

"While we are disappointed in the DEFEND-1 results of otelixizumab, we remain committed to the development and commercialization of the candidates in our pipeline, each of which has a distinct mechanism and target for correcting abnormal immune responses," said Douglas J. Ringler, VMD, President and Chief Executive Officer of Tolerx. "Our immunotherapy candidates represent some of the latest scientific advances in harnessing the immune system for therapeutic benefit, including TRX518 which is a showpiece of our pipeline as an immunotherapy to treat cancer."

"Clearly these are disappointing data, but we are committed to working with Tolerx to better understand the results of this study and determine the way forward," said Jackie Parkin, Medicines Development Leader, GlaxoSmithKline.

Tolerx Pipeline

In addition to otelixizumab, Tolerx has four product candidates in various stages of development, and each candidate is based on Tolerx's immunology expertise in understanding how therapies can be designed
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
2. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
3. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
4. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
5. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
6. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
7. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
8. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
9. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
10. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
11. GlaxoSmithKline Wins Environmental Stewardship Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
(Date:1/14/2014)... 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - ... instrumentation to place and insert the screw accurately - ... (e.g. ligament) repair or reconstruction as it holds the ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
(Date:7/9/2014)... have been linked to an emerging fungal disease ... Institute for Mathematical and Biological Synthesis (NIMBioS) shows ... , In a series of mathematical models, researchers ... internal organs in frogs, could cause extinction of ... exposed to the virus every few years, a ...
(Date:7/9/2014)... is one of the most important organs in the ... utilize our food properly this is its synthesis ... our organism this is its detoxification function. Lack ... food all damage the liver. The resulting diseased cells ... and life-threatening liver failure. According to the German Liver ...
(Date:7/9/2014)... , , , , ... , , , AUDIO: , ... approximately 30cm from the bullet... , , Click here for ... , , , , , ... , , , , , University of Southampton researchers, with assistance from the Ministry of ...
(Date:7/8/2014)... longevity and cardiovascular health as other healthy mature individuals, ... American Journal of Transplantation . The findings may provide ... transplant professionals caring for them. , Over the past ... years and older has become more common. Given the ... the removal of a kidney could make older donors ...
(Date:7/8/2014)... be three times higher when auditors were visible to ... according to a study in a major Canadian acute ... the Hawthorne effect in hand hygiene compliance monitoring using ... today on-line in the BMJ Quality & Safety ... did the study as part of her Master,s thesis ...
Breaking Medicine News(10 mins):Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:Study finds kidney donation safe for healthy older adults 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3
... Study Reveals the Most Common Reasons Why Total Hip ... thousands of patients undergo total hip replacement surgery in ... disease and other related hip problems. According to ... of The Journal of Bone and Joint Surgery ...
... Jan. 2 Joan Lunden, the nation,s,longest-running morning ... two decades. During her tenure she reported ... two Royal weddings. One of the most,visible ... of her career to,educating Americans about health and ...
... ATLANTA, Jan. 2 Publix, Procter & Gamble, and,Special ... people with,intellectual disabilities achieve their dreams. Now they,re ... Special Olympics. , 1. Support ... by,purchasing your favorite P&G products like Tide, Pampers, Bounty ...
... tips on how to avoid injury while performing winter ... snow from your driveway and sidewalks can be physically ... proper health and safety precautions, says the American Academy ... than 118,000 people were treated in U.S. hospital emergency ...
... keep colds and flu at bay , , FRIDAY, Jan. 2 ... there,s one tidbit that doctors stand by as the best way ... free of germs is one of the simplest and most effective ... other infectious disease, experts say. , "Disease transmission is hand-to-hand combat, ...
... Va.In a study to determine the diagnostic value of ... cancer, researchers were able for the first time to ... and normal residual thyroid tissue directly after surgery. , ... an article in the January issue of The ...
Cached Medicine News:Health News:Replacing Your Total Hip Replacement 2Health News:Replacing Your Total Hip Replacement 3Health News:Joan Lunden Inks Three-Year Deal to Host Health Corner(R) Television Series 2Health News:'Be A Fan' of Special Olympics Throughout January 2Health News:Shovel Snow Safely 2Health News:To Protect Yourself, Wash Those Germs Away 2Health News:To Protect Yourself, Wash Those Germs Away 3Health News:To Protect Yourself, Wash Those Germs Away 4Health News:Molecular imaging enables earlier, individualized treatment of thyroid cancer 2
Subretinal Fluid Cannula, Curved; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip; Curved at 65°....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
...
PremierEdge™ Slit Knives....
Medicine Products: